This site is intended for US healthcare professionals
Alkermes logo
Alkermes logo
Educational Resources
Resources Home
Congresses
Product Information
Our Pipeline
Knowledge Vault
Contact an MSL
Medical Information
Research & Medical Grants

Product Information

ARISTADA®

(aripiprazole lauroxil)

Prescribing Information Medication Guide
ARISTADA INITIO®

(aripiprazole lauroxil)

Prescribing Information Medication Guide

Publications

Alkermes Sponsored Phase 3 Clinical Trials

Aug 2015
A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia
The Journal of Clinical Psychiatry
AUTHOR(S)

Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, Bose A, Stankovic S, Silverman BL, Ehrich EW.

View on PubMed
Aug 2019
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia
CNS Spectrums
AUTHOR(S)

Nasrallah HA, Aquila R, Du Y, Stanford AD, Claxton A, Weiden PJ.

View on PubMed
May 2020
Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study
The Journal of Clinical Psychiatry
AUTHOR(S)

Weiden PJ, Claxton A, Kunovac J, Walling DP, Du Y, Yao B, Yagoda S, Bidollari I, Keane E, Cash E.

View on PubMed
Contact Us Terms of Use Privacy Policy www.alkermes.com

The product information provided on this site is intended only for healthcare professionals in the United States and is for informational purposes only. This site is designed to provide background and scientific findings concerning Alkermes products and areas of therapeutic interest. Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

If you have a suspected Adverse Event or Product Complaint to report, please contact us by phone at 888-235-8008 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Your use of this information is subject to the terms and conditions of our Privacy Policy.

© 2024 Alkermes, Inc. All rights reserved. MA-004230

Please review our Privacy Policy.

By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Policy. Learn more.

Close
This site is intended for US healthcare professionals
Alkermes Logo
Educational Resources
Congresses
Product Information
Our Pipeline
Contact an MSL
Medical Information
Research & Medical Grants